Please use this identifier to cite or link to this item:
https://doi.org/10.1186/1475-2840-4-13
Title: | Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: Baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481] | Authors: | Keech, A.C Scott, R. Best, J. |
Keywords: | antidiabetic agent fenofibrate high density lipoprotein high density lipoprotein cholesterol low density lipoprotein cholesterol peroxisome proliferator activated receptor agonist placebo triacylglycerol antilipemic agent apolipoprotein B cholesterol fenofibrate high density lipoprotein cholesterol low density lipoprotein cholesterol triacylglycerol adult aged article clinical trial controlled clinical trial controlled study coronary risk double blind procedure drug mechanism female high risk patient human hypertension ischemic heart disease long term care major clinical study male metabolic syndrome X non insulin dependent diabetes mellitus obesity randomized controlled trial treatment outcome waist circumference Australia blood cardiovascular disease coronary artery disease diabetes mellitus Finland middle aged New Zealand non insulin dependent diabetes mellitus obesity Aged Apolipoproteins B Australia Cardiovascular Diseases Cholesterol Cholesterol, HDL Cholesterol, LDL Coronary Disease Diabetes Complications Diabetes Mellitus, Type 2 Double-Blind Method Female Fenofibrate Finland Humans Hypolipidemic Agents Male Middle Aged New Zealand Obesity Placebos Triglycerides |
Issue Date: | 2005 | Citation: | Keech, A.C, Scott, R., Best, J. (2005). Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: Baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]. Cardiovascular Diabetology 4 : 13. ScholarBank@NUS Repository. https://doi.org/10.1186/1475-2840-4-13 | Rights: | Attribution 4.0 International | Abstract: | Objective: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study is examining the effects of long-term fibrate therapy on coronary heart disease (CHD) event rates in patients with diabetes mellitus. This article describes the trial's run-in phase and patients' baseline characteristics. Research design and methods: FIELD is a double-blind, placebo-controlled trial in 63 centres in 3 countries evaluating the effects of fenofibrate versus placebo on CHD morbidity and mortality in 9795 patients with type 2 diabetes mellitus. Patients were to have no indication for lipid-lowering therapy on randomization, but could start these or other drugs at any time after randomization. Follow-up in the study was to be for a median duration of not less than 5 years and until 500 major coronary events (fatal coronary heart disease plus nonfatal myocardial infarction) had occurred. Results: About 2100 patients (22%) had some manifestation of cardiovascular disease (CVD) at baseline and thus high risk status. Less than 25% of patients without CVD had a (UKPDS determined) calculated 5-year CHD risk of <5%, but nearly all had a 5-year stroke risk of <10%. Despite this, half of the cohort were obese (BMI >30), most were men, two-thirds were aged over 60 years, and substantial proportions had NCEP ATP III features of the metabolic syndrome independent of their diabetes, including low HDL (60%), high blood pressure measurement (41%), high waist measurement (65%), and raised triglycerides (52%). After a 6-week run-in period before randomisation with all participants receiving 200 mg comicronized fenofibrate, there were declines in total and LDL cholesterol (10%) and triglycerides (26%) and an increase in HDL cholesterol (6.5%). Conclusion: The study will show the effect of PPAR-alpha agonist action on CHD and other vascular outcomes in patients with type 2 diabetes including substantial numbers with low to moderate CVD risk but with the various components of the metabolic syndrome. The main results of the study will be reported in late 2005. © 2005 Keech, licensee BioMed Central Ltd. | Source Title: | Cardiovascular Diabetology | URI: | https://scholarbank.nus.edu.sg/handle/10635/178030 | ISSN: | 14752840 | DOI: | 10.1186/1475-2840-4-13 | Rights: | Attribution 4.0 International |
Appears in Collections: | Staff Publications Elements |
Show full item record
Files in This Item:
File | Description | Size | Format | Access Settings | Version | |
---|---|---|---|---|---|---|
10_1186_1475-2840-4-13.pdf | 248.31 kB | Adobe PDF | OPEN | None | View/Download |
This item is licensed under a Creative Commons License